Європейський Союз - португальська - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozina propanodiol mono-hidratada - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas em diabetes - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. além de outros medicamentos para o tratamento da diabetes tipo 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Європейський Союз - португальська - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozina propanodiol mono-hidratada - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas em diabetes - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. além de outros medicamentos para o tratamento da diabetes tipo 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Європейський Союз - португальська - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - drogas usadas em diabetes - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Європейський Союз - португальська - EMA (European Medicines Agency)

genzyme europe bv - cloridrato de sevelamer - hyperphosphatemia; renal dialysis - todos os outros produtos terapêuticos - tasermidade é indicada para o controle da hiperfosfatemia em pacientes adultos que recebem hemodiálise ou diálise peritoneal. o cloridrato de sevelamer deve ser utilizado no contexto de uma abordagem terapêutica múltipla, que poderia incluir suplementos de cálcio, 1,25 dihidroxi vitamina d3 ou um dos seus análogos para controlar o desenvolvimento da doença óssea renal.

Європейський Союз - португальська - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - paciromero sorbitex cálcio - hipercalemia - medicamentos para o tratamento da hipercalemia e hiperfosfatemia - veltassa é indicado para o tratamento da hipercalemia em adultos.

Європейський Союз - португальська - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas em diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Європейський Союз - португальська - EMA (European Medicines Agency)

bayer ag - finerenone - renal insufficiency, chronic; diabetes mellitus, type 2 - agentes que atuam no sistema renina-angiotensina - kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.

Європейський Союз - португальська - EMA (European Medicines Agency)

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - preparações antianêmicas - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Португалія - португальська - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

baxter médico-farmacêutica, lda. - aminoácidos - solução para perfusão - associação - lisina 11 mg/ml ; valina 7.6 mg/ml ; fenilalanina 4.2 mg/ml ; alanina 8 mg/ml ; triptofano 2 mg/ml ; metionina 2.4 mg/ml ; isoleucina 6.7 mg/ml ; Ácido glutâmico 10 mg/ml ; tirosina 0.45 mg/ml ; histidina 3.8 mg/ml ; cisteína 1.89 mg/ml ; glicina 4 mg/ml ; taurina 0.6 mg/ml ; arginina 8.4 mg/ml ; treonina 3.7 mg/ml ; serina 4 mg/ml ; prolina 3 mg/ml ; leucina 10 mg/ml ; Ácido aspártico 6 mg/ml ; ornitina, cloridrato 3.18 mg/ml - amino acids - n/a - duração do tratamento: curta ou média duração

Португалія - португальська - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

baxter médico-farmacêutica, lda. - aminoácidos - solução para perfusão - associação - lisina 11 mg/ml ; valina 7.6 mg/ml ; fenilalanina 4.2 mg/ml ; alanina 8 mg/ml ; triptofano 2 mg/ml ; metionina 2.4 mg/ml ; isoleucina 6.7 mg/ml ; Ácido glutâmico 10 mg/ml ; tirosina 0.45 mg/ml ; histidina 3.8 mg/ml ; cisteína 1.89 mg/ml ; glicina 4 mg/ml ; taurina 0.6 mg/ml ; arginina 8.4 mg/ml ; treonina 3.7 mg/ml ; serina 4 mg/ml ; prolina 3 mg/ml ; leucina 10 mg/ml ; Ácido aspártico 6 mg/ml ; ornitina, cloridrato 3.18 mg/ml - amino acids - n/a - duração do tratamento: curta ou média duração